Inflammatory bowel disease: Research
1. Pannexins can mimic IBD symptoms
A collaborative research from the Hotchkiss Brain Institute and Snyder University of Chronic Diseases have unearthed a pathway that gives rise to the various symptoms in inflammatory bowel disease. Molecules termed as ‘pannexins’ are the prime mediators of the gut neurons and their consequent death. Due to the death of the neurons lining the intestinal mucosa, discomforting symptoms may arise ranging from GI tract bleeding and acute abdominal pain. Brian Gulbransen, the lead author said that finding pannexins as the root cause of the symptoms may further lead to positive solutions in preventing IBD. Animal models were used to identify these pannexins in mice.
2. Calorie restricted diet may not be good for IBD
Michigan State University scientists have come with a striking result that says that low calorie diet amy actually contributes to death due to inflammation caused by pathogenic bacteria in the intestine and leads to a fatal IBD. Researchers felt that a low calorie diet may weaken the immune system and make the individual more prone to pathogenic attacks from potent bacteria such as Heliobacter pylori. The immune system then cannot combat with the chronic infection of the intestinal tract. This may lead to severe repercussions on the body and lead to even death. Jennifer Fenton, the assistant professor revealed that the research has been published in the latest edition of World Journal of Gastroenterology.
3. New light on efficacy of CLA in Crohn’s disease
Patients suffering from Crohn’s disease showed a marked improvement and relief from symptoms when given additional supplements of conjugated linoleic acid (CLA). The research team at Virginia Tech, which is from the Nutritional Immunology and Molecular Medicine Laboratory, have discovered positive information about the role of CLA in Crohn’s disease. In their extensive study, they observed that those who took an intake of CLA had definite improvement in the quality of life than those who did not. Professor Kim L. Isaacs. A professor of Gastroenetrology was elated by these positive findings and felt that it will be further evaluated in a randomized controlled trial.
4. Avaxia awarded $1.5 M for research and work on IBD by NIH
A private biotech organization, Avaxia Biologics Inc. has been awarded a cool $1.5 million grant to develop orally active antibodies for the effective treatment of IBD and other GI tract diseases. The funding will be over a period of two years by which time Avaxia needs to come up with an antibody therapy for the inflammatory bowel disease. Avaxia has already demonstrated the efficacy of AVX-479 in mice models with great success. Clinical trials will soon be embarked on, said Barbara Fox, the founder and CEO of Avaxia. She felt that AVX-470 had the potential to become the leading choice of therapy in inflammatory bowel disease in times to come. If successful, AVX-470 will be the first of its kind orally active anti-TNF antibody for IBD.
5. Aerpio’s AKB-9778 phase 1 trial on DME and IBD positive
Advanced discoveries for the treatment of IBD and DME (diabetic macular edema) have led to positive feedback in the phase 1 trial of Aerpio Therapeutics, a biopharma company. AKB-9778 is a human protein inhibitor that acts against the protein HPTPβ. This protein also known as human protein tyrosine phosphatase beta inhibitor activates receptors known as Tie2 leading to significant relief of symptoms. AKB-9778 can be self administered making bit more patient friendly and easy to use. Keven Peters, the chief scientific officer said that they were looking forward to more encouraging findings in their next phase trials that begin in the second quarter of 2012.